TAS 3351
Alternative Names: TAS-3351Latest Information Update: 14 Nov 2023
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 03 May 2023 Phase-I/II clinical trials in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in United Kingdom, Germany, Netherlands, South Korea, Spain, France after May 2023 (PO) (NCT05765734)
- 03 May 2023 Phase-I/II clinical trials in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA, Japan (PO) (NCT05765734)
- 16 Mar 2023 Taiho Oncology plans a phase I/II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable) by March 2023 (PO) (NCT05765734)